Onconeural antibodies are essential to diagnose paraneoplastic neurological syndromes

Acta Neurologica Scandinavica

Volumn 113, Issue SUPPL. 183, 2006, Pages 64-68

  Honnorat, J ^a,b,c,d  

^a HÔPITAL NEUROLOGIQUE   (France)

^b INSERM   (France)

^c Institut Federatif des Neurosciences de Lyon   (France)

^d UNIVERSITÉ LYON 1   (France)

Author keywords

Auto antibodies; Cancer; Paraneoplasia; Tumour

Indexed keywords

AMPHIPHYSIN ANTIBODY; ANTIBODY; ANTIGEN; CRMP5 ANTIBODY; FLUORODEOXYGLUCOSE; HU ANTIBODY; IMMUNOGLOBULIN; MA2 ANTIBODY; ONCONEURAL ANTIBODY; ONCONEURAL ANTIGEN; RI ANTIBODY; STEROID; TR ANTIBODY; UNCLASSIFIED DRUG; VOLTAGE GATED CALCIUM CHANNEL ANTIBODY; YO ANTIBODY; NERVE PROTEIN;

ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIGEN SPECIFICITY; AUTOIMMUNITY; BRAIN INFECTION; BRAIN ISCHEMIA; CANCER; CANCER STAGING; CANCER THERAPY; CHRONOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; DIAGNOSTIC VALUE; DISEASE COURSE; DISEASE SEVERITY; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; MEDICAL SPECIALIST; METABOLIC DISORDER; METASTASIS; NERVOUS SYSTEM; NEUROLOGIC DISEASE; NEUROLOGY; PARANEOPLASTIC NEUROPATHY; PATHOGENESIS; PATIENT REFERRAL; PHYSICAL DISABILITY; POSITRON EMISSION TOMOGRAPHY; RARE DISEASE; RISK FACTOR; SEROLOGY; TUMOR; BLOOD; IMMUNOLOGY; REVIEW;

ANTIBODIES; HUMANS; NERVE TISSUE PROTEINS; PARANEOPLASTIC SYNDROMES, NERVOUS SYSTEM;

EID: 33645500591     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2006.00620.x     Document Type: Conference Paper

References (23)

1. P osner JB. Neurologic complications of cancer.
2. G raus F D elattre JY A ntoine JC et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 2004 75 1135 40.
3. K eime -G uibert F G raus F F leury A et al. Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone. J Neurol Neurosurg Psychiatry 2000 68 479 82.
4. V ernino S O'N eill BP M arks RS et al. Immunomodulatory treatment trial for paraneoplastic neurological disorders. Neuro-oncol 2004 6 55 62.
5. P eterson K R osenblum MK P osner JB. Paraneoplastic cerebellar degeneration: a clinical analysis of 55 anti-Yo antibody-positive patients. Neurology 1992 42 1931 7.
6. R ojas I G raus F K eime -G uibert F R ene R D elattre JY R amon JM et al. Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies. Neurology 2000 55 713 15.
7. G raus F K eime -G uibert F R eñé R et al. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain 2001 124 1138 48.
8. H onnorat J A ntoine JC D errington E A guera M B elin MF. Antibodies to a subpopulation of glial cells and a 66 kD developmental protein in patients with paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 1996 61 270 8.
9. R ogemond V H onnorat J. Anti-CV2 autoantibodies and paraneoplastic neurological syndromes. Clin Rev All Immunol 2000 19 48 57.
10. L uque FA F urneaux HM F erziger R et al. Anti-Ri: an autoantibody associated with paraneoplastic opsoclonus and breast cancer. Ann Neurol 1991 29 241 51.
11. B ernal F S hams'ili S R ojas I S anchez -V alle R S aiz A D almau J et al. Anti-Tr antibodies as markers of paraneoplastic cerebellar degeneration and Hodgkin's disease. Neurology 2003 60 230 4.
12. F olli F S olimena M C ofiell R et al. Autoantibodies to a 128-kd synaptic protein in three women with the stiff-man syndrome and breast cancer. N Engl J Med 1993 328 546 51.
13. A ntoine JC A bsi L H onnorat J et al. Anti-amphiphysin antibodies are associated with various paraneoplastic neurological syndromes and tumours. Arch Neurol 1999 56 172 7.
14. D almau J G raus F V illarejo A et al. Clinical analysis of anti-Ma2-associated encephalitis. Brain 2004 127 1831 44.
15. M otomura M L ang B J ohnston I P alace J V incent A N ewsom -D avis J. Incidence of serum anti-P/O-type and anti-N-type calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome. J Neurol Sci 1997 147 35 42.
16. G raus F L ang B P ozo -R osich P et al. P/Q type calcium-channel antibodies in paraneoplastic cerebellar degeneration with lung cancer. Neurology 2002 59 764 6.
17. M ason WP G raus F L ang B et al. Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert-Eaton mysthenic syndrome. Brain 1997 120 1279 300.
18. C artalat -C arel S C amdessanche JP R icard D et al. The paraneoplastic neurological syndrome associated with anti-CV2 (anti-CRMP5) antibodies is different from that of anti-Hu antibodies. Neurology 2004 62 A476 7.
19. K im YI. Passively transferred Lambert-Eaton syndrome in mice receiving purified IgG. Muscle Nerve 1986 9 523 30.
20. R icard D R ogemond V C harrier E et al. Isolation and expression pattern of human Unc-33-like phosphoprotein 6/collapsin response mediator protein 5 (Ulip6/CRMP5): coexistence with Ulip2/CRMP2 in Sema3a-sensitive oligodendrocytes. J Neurosci 2001 21 7203 14.
21. P lonquet A G arcia -P ons F F ernandez E et al. Peptides derived from the onconeural HuD protein can elicit cytotoxic responses in HHD mouse and human. J Neuroimmunol 2003 142 93 100.
22. 18FDG-PET improves tumor detection in patients with paraneoplastic neurological syndromes. Brain 2004 127 2331 8.
23. 18F]fluoro- 2-deoxyglucose-PET scanning in the diagnosis of paraneoplastic neurological disorders. Brain 2001 124 2223 31.